PMS-Irbesartan 300 mg – DIN 02317087
PMS-Irbesartan is Irbesartan 300 mg (tablet), sold in Canada. It is used for high blood pressure, a weak heart and kidney disease from diabetes. It is supplied by Pharmascience Inc. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.
Sold in Canada
Irbesartan 300 mg
- Brand
- PMS-Irbesartan
- Strength
- 300 mg
- Used for
- High blood pressure, a weak heart and kidney disease from diabetes
- Form
- Tablet
- Manufacturer
- Pharmascience Inc
- Drug class
- ARB (blood pressure medicine)
- Sold in
- Canada
- DIN
- 02317087
Source: Health Canada's Drug Product Database. Last checked .
Report a mistake
What is Irbesartan used for?
Irbesartan is used for high blood pressure, a weak heart and kidney disease from diabetes.
- Medicine type
- ARB (blood pressure medicine)
Official uses from the US prescribing label
Hypertension
Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Irbesartan tablets may be used alone or in combination with other antihypertensive agents.
Nephropathy in Type 2 Diabetic Patients
Irbesartan tablets are indicated for the treatment of diabetic nephropathy in patients with type 2 diabetes and hypertension, an elevated serum creatinine, and proteinuria (>300 mg/day). In this population, irbesartan tablets reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end-stage renal disease (need for dialysis or renal transplantation).
From the FDA-approved label on DailyMed (published Sep 28, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your medicine? Check the box
- The box or bottle shows DIN 02317087.
- It names PMS-Irbesartan, Irbesartan 300 mg.
- A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.
Sold in Canada as PMS-Irbesartan by Pharmascience Inc.
In Canada: prescription only.
Ingredients
Active: Irbesartan
Other Irbesartan pills
- 2772 Irbesartan 150 mg White, oval, 14 mm Used for high blood pressure and a weak heart
- SG 161 Irbesartan 150 mg White, oval, 14 mm Used for high blood pressure and a weak heart
- HH 330 Irbesartan 150 mg White, oval, 12 mm Used for high blood pressure and a weak heart
- ML95 Irbesartan 150 mg White, oval, 14 mm Used for high blood pressure and a weak heart
- HU 150 Irbesartan 150 mg White, oval, 14 mm Used for high blood pressure and a weak heart
- L132 150 Irbesartan 150 mg White, oval, 14 mm Used for high blood pressure and a weak heart
- 159 H Irbesartan 150 mg White, capsule, 11 mm Used for high blood pressure and a weak heart
- LU M12 Irbesartan 150 mg White, oval, 14 mm Used for high blood pressure and a weak heart